AbbVie Inc. (NYSE:ABBV) entered into an agreement to acquire DJS Antibodies Ltd for $350 million subsequent to September 30, 2022. Under the terms of the agreement, AbbVie will pay DJS shareholders approximately $255 million in cash at closing and DJS shareholders will remain eligible for $95 million upon the achievement of certain development milestones related to the success of the DJS-002 program. AbbVie anticipates retaining all current DJS employees and its facility in Oxford. DJS is backed by founding investors Oxford Science Enterprises and Johnson & Johnson Innovation Ltd., along with LifeArc, Sedgwick Claims Management Services, Inc. and Amgen Ventures.

Centerview Partners UK LLP acted as financial advisor to DJS Antibodies. Graham Defries and Kenny Walker-Durrant of Goodwin Procter LLP and Cooley LLP acted as legal advisor to DJS Antibodies.

AbbVie Inc. (NYSE:ABBV) completed the acquisition of DJS Antibodies Ltd on October 20, 2022. Catherine Dargan, Gregor Frizzell, Camilla Rogers, Kyle Rabe, Winsome Cheung, Guy Dingley and Antonio Michaelides of Covington & Burling LLP acted as legal advisor to AbbVie Inc. (NYSE:ABBV).